News
Revenues beat expectations, earnings per share lag
Evolent Health (NYSE:EVH) Results for the first quarter of 2024
Main financial results
-
Revenue: US$639.7 million (50% increase compared to 1Q 2023).
-
Net loss: US$25.2 million (loss reduced by 3.9% compared to 1Q 2023).
-
Loss of US$0.22 per share (improved from loss of US$0.24 in 1Q 2023).
earnings and revenue growth
All numbers shown in the chart above are for the period of the last 12 months (TTM)
Evolent Health’s revenue beats expectations, EPS falls short
Revenue surpassed analyst estimates by 6.8%. Earnings per share (EPS) missed analyst estimates by 65%.
Looking ahead, revenue is forecast to grow 14% per year on average over the next 3 years, compared to an 11% growth forecast for the US healthcare industry.
Performance of American healthcare industry.
The company’s shares fell 9.7% from the previous week.
Risk analysis
It is still necessary to consider the ever-present specter of investment risk. We’ve identified 1 warning sign with Evolent Healthand understanding it should be part of your investment process.
Do you have feedback on this article? Worried about the content? Get in touch with us directly. Alternatively, email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your objectives or your financial situation. Our goal is to bring you long-term focused analysis driven by fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St has no position in any of the stocks mentioned.